Although PDE10A inhibition has shown promise as a novel target of the treatment of schizophrenia, 15 recently the first positron emission tomography (PET) study of PDE10A expression in patients with ...

Phosphodiesterases (PDEs) are a large family of enzymes that specifically hydrolyze the second messengers cyclic AMP and/or cyclic GMP. There are 11 distinct PDE isoenzymes, differing in their ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. MILAN — A basket study of a new topical ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function ...

To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...

The FDA approved inhaled ensifentrine (Ohtuvayre) as maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults, drugmaker Verona Pharma announced on Wednesday. A first-in-class ...

In a placebo-controlled trial, treatment with the preferential phosphodiesterase 4B inhibitor BI 1015550 prevented a decrease in lung function over a 12-week period in patients with idiopathic ...

New research in this week’s Journal of Neuroscience sustains hopes of boosting cognition through enhancement of the cyclic AMP (cAMP) signaling pathway that turns on memory genes. Using genetic and ...

Mironid Ltd. has synthesized phosphodiesterase PDE4 activators reported to be useful for the treatment cancer, hyperparathyroidism, autosomal dominant polycystic kidney disease and autosomal recessive ...

Assessment of IL-6, IL-8, bFGF, PDGF-BB, and VEGF-A as prognostic and predictive biomarkers for anti-VEGF in metastatic colorectal cancer (mCRC). Ultra-high-quality sequencing assay for comprehensive ...

Serum pharmacoproteomics of erlotinib-treated advanced prostate cancer patients: A SELDI-TOF mass spectrometry analysis No significant financial relationships to disclose. This is an ASCO Meeting ...

LONDON--(BUSINESS WIRE)--The global phosphodiesterase (PDE) inhibitors market is expected to post a CAGR close to 6% during the period 2019-2023, according to the latest market research report by ...